RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics, and its subsidiary, Aclipse Two, Inc (“Aclipse”), an innovative biopharmaceutical company developing life-changing treatments for patients with ...
RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics and its subsidiary Aclipse One Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company, today announced that the Company has ...
Chong Kun Dang partner Aclipse launches Mayo Clinic phase 2 trial of lobeglitazone for gastroparesis
Chong Kun Dang said on the 27th that its global partner, Aclipse Therapeutics, signed an agreement with the Mayo Clinic for a phase 2 clinical trial of the gastroparesis treatment candidate "M107 ...
KING OF PRUSSIA, Pa., November 17, 2025--(BUSINESS WIRE)--Aclipse Therapeutics LLC ("Aclipse" or "the Company") today announced that it has entered into a clinical collaboration and Know-How Agreement ...
M102 is a disease-modifying drug candidate for motor neuron disease (MND) that was discovered by Sheffield scientists in 2013 University of Sheffield partnership with Aclipse Therapeutics awarded a £1 ...
Chong Kun Dang announced on the 27th that its global license partner for the novel diabetes drug lobeglitazone (brand name Duvie), Aclipse Therapeutics, has signed an agreement with the Mayo Clinic in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results